Benign Prostatic Hyperplasia Treatment Market Research Report Information By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy and Combination Drug Therapy), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032

Global Benign Prostatic Hyperplasia Treatment Market Overview

The Benign Prostatic Hyperplasia Treatment Market Size was valued at USD 11.2 Billion in 2022 and is projected to grow from USD 11.8 Billion in 2023 to USD 18.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.50% during the forecast period (2023 - 2032). Benign prostatic hyperplasia is becoming more common, and tailored medicine technology is advancing, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Benign Prostatic Hyperplasia Treatment Market Trends

• Increasing prevalence of benign prostatic hyperplasia is driving the market growth

Men frequently experience symptoms in the lower urinary tract due to benign prostatic hyperplasia, a non-cancerous development of prostate tissue. BPH is regarded as a typical aspect of male aging and is hormonally reliant on the generation of testosterone and dihydrotestosterone (DHT). By the ages of 60 and 85, 50% and 90% of males, respectively, show histopathologic benign prostatic hyperplasia. It is estimated that 14 million men in the US and 30 million men worldwide experience the symptoms of benign prostatic hyperplasia. BPH was diagnosed in over 7,600,000 persons in 2010, and grew by 1.2 million in 2017 according to data from the Health Insurance Review and Assessment (HIRA) agency in 2018. This reflects a total increase of 58% from 2010 and an annual growth of roughly 7%.

Given that benign prostatic hyperplasia is a condition that typically affects men as they age, the aging population is thought to be a significant factor in the rise in benign prostatic hyperplasia incidence, particularly among geriatric men. Thus, as this population segment expands, there will be a demand for suitable treatments in important markets. China, for instance, is thought to have the world's highest geriatric population; by 2050, that number is expected to increase from 10.1% in 2015 to 26.8% (source: US Census Bureau). According to the WHO, there may be 100 million Chinese citizens who are 80 years of age or older by 2050. According to NHS data, there were five million men in the U.K. in 2019. By the end of 2050, there should be approximately nine million men living there.

The rise in benign prostatic hyperplasia prevalence and the expanding worldwide male geriatric population are both important factors driving the growth of the BPH treatments market. In addition, increased sympathetic nerve activity, altered endocrine status, a heightened inflammatory response, and oxidative stress all have a role in the development of BPH in obese individuals. The body's hormonal fluctuations also lead to BPH by causing prostate enlargement. As a result, this fuels the market for treatments for benign prostatic hyperplasia. Increased government and non-profit initiatives, as well as key players in the Benign Prostatic Hyperplasia Therapeutics market, to raise awareness for various urological disorders, including benign prostatic hyperplasia, also play a critical role in doing so and thereby support market growth.

The expiration of the patency of significant branded products has sparked the development of numerous generic medications, collaboration among the key players for the development of new BPH therapeutics for better drug efficacy and safe therapy for already existing medications, as well as upcoming new molecular entities. These developments have further fueled the market's expansion. A significant increase in healthcare spending around the world has further stimulated the market. Population growth, particularly among the elderly, and greater use of medical services are the main causes of the rise in healthcare costs. However, it is anticipated that a higher adoption rate of minimally invasive surgical therapies than of BPH therapeutics will restrain market expansion. Thus, driving the Benign Prostatic Hyperplasia Treatment market revenue.

Benign Prostatic Hyperplasia Treatment Market Segment Insights

Benign Prostatic Hyperplasia Treatment Therapeutic Class Insights

The Market segments of Benign Prostatic Hyperplasia Treatment, based on therapeutic class, includes alpha blockers, 5- alpha reductase inhibitors, phosphodiesterase-5 inhibitors, others. Alpha-blockers segment dominated the global market in 2022. The prostate and bladder neck muscles are relaxed by alpha-blockers, facilitating easier urine flow. For males with mild to severe symptoms, the first line of treatment is typically an alpha-blocker, which acts immediately.

Benign Prostatic Hyperplasia Treatment Therapy Insights

The Benign Prostatic Hyperplasia Treatment Market segmentation, based on therapy, includes mono drug therapy and combination drug therapy. Mono drug therapy segment dominated the market of Benign Prostatic Hyperplasia Treatment in 2022. This is related to the rising demand for alpha-blockers, which help to treat the condition by relaxing the muscles in the prostate and bladder neck and allowing urine to flow more easily.

Figure 1: Benign Prostatic Hyperplasia Treatment Market, by Therapy, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Benign Prostatic Hyperplasia Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Benign Prostatic Hyperplasia Treatment Market dominated this market in 2022 (45.80%). This is due to the high prevalence of BPH and other lower urinary tract symptoms that go along with it. For instance, according to information from the National Institute of Health, the prevalence of benign prostatic hyperplasia can reach 50% to 60% in guys in their 60s and rise to 80% to 90% in those over 70. Further, the U.S. market of Benign Prostatic Hyperplasia Treatment held the largest market share, and the Canada market of Benign Prostatic Hyperplasia Treatment was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

Figure 2: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Benign Prostatic Hyperplasia Treatment market accounted for the healthy market share in 2022. This is due to an increase in BPH prevalence, unhealthy lifestyles that cause obesity, the presence of important actors, and rising healthcare costs in the area. Further, the German market of Benign Prostatic Hyperplasia Treatment held the largest market share, and the U.K market of Benign Prostatic Hyperplasia Treatment was the fastest growing market in the European region

The Asia Pacific Benign Prostatic Hyperplasia Treatment market is expected to register significant growth from 2023 to 2032. This is brought on by an increase in the region's elderly population, R&D activity, urological disease outbreaks, unmet medical needs, and investments in the healthcare industry. Moreover, China’s market of Benign Prostatic Hyperplasia Treatment held the largest market share, and the Indian market of Benign Prostatic Hyperplasia Treatment was the fastest growing market in the Asia-Pacific region.

Benign Prostatic Hyperplasia Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Benign Prostatic Hyperplasia Treatment, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Benign Prostatic Hyperplasia Treatment Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Benign Prostatic Hyperplasia Treatment Industry to benefit clients and increase the market sector. In recent years, the Benign Prostatic Hyperplasia Treatment Industry has offered some of the most significant advantages to medicine. Major players in the market of Benign Prostatic Hyperplasia Treatment, including Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Limited, are attempting to increase market demand by investing in research and development operations.

Pharmaceuticals of all kinds are discovered, developed, produced, and sold by Astellas Pharma Inc (Astellas). Marketed treatments for the treatment of a variety of urological disorders, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation are included in the company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anemia linked to chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis, and non-dialysis patients. With the help of a network of subsidiaries and affiliates, it conducts business in the Americas, Australia, Europe, Asia, and Oceania. Tokyo, Japan serves as the headquarters of Astellas. In June 2022, Xyphos Biosciences, Inc., a fully owned subsidiary of Astellas, and GO therapies, Inc., announced that they had entered into a strategic research collaboration and license agreement to develop new immuno-oncology therapies.

GSK plc (GSK) is a healthcare organization with a focus on the development, production, and marketing of generic medications, speciality medications, and vaccines. It provides medications to treat conditions like HIV, respiratory, cancer, immuno-inflammation, antiviral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, antibacterial, dermatological, and uncommon disorders. The business also sells over-the-counter (OTC) items for gastrointestinal disorders, nutrition, skin health, and pain treatment. Hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis are just a few of the diseases that are covered by GSK's vaccine portfolio. The business offers its goods through wholesalers, pharmacies, hospitals, doctors' offices, and other organizations all around the world. The UK's Brentford, in Middlesex, serves as the home base for GSK. A combination between GlaxoSmithKline (GSK) and Pfizer Inc. was announced for July 2020.

Key Companies in the Benign Prostatic Hyperplasia Treatment market include

• Air Liquide


• Abbott Laboratories


• AbbVie (Allergan Plc)


• Astellas Pharma Inc.


• Boehringer Ingelheim Pharma GmbH & Co. KG


• Eli Lilly and Company


• GlaxoSmithKline plc.


• Merck & Co., Inc. (Merck Sharp & Dohme Corp)


• Pfizer Inc.


• Sanofi


• Teva Pharmaceutical Industries Limited

Benign Prostatic Hyperplasia Treatment Industry Developments

October 2020 A merger between Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited was announced; it is anticipated to close in 2023. The goal of this merger is to establish a global leader in the creation and marketing of cutting-edge therapies for people with benign prostatic hyperplasia (BPH).

Benign Prostatic Hyperplasia Treatment Market Segmentation

Benign Prostatic Hyperplasia Treatment Therapeutic Class Outlook

• Alpha Blockers


• 5- Alpha Reductase Inhibitors


• Phosphodiesterase-5 Inhibitors


• Others

Benign Prostatic Hyperplasia Treatment Therapy Outlook

• Mono Drug Therapy


• Combination Drug Therapy

Benign Prostatic Hyperplasia Treatment Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America